GlassScriptPhysician profile
Alice Kavitha David
NPI 1780661066
$22,778.02
in general payments reported to CMS, 2019-2025
89 companies · $2,765 in 2025
The $2,765 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,247 · 2020: $2,358 · 2021: $3,445 · 2022: $3,846 · 2023: $3,420 · 2024: $3,696 · 2025: $2,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,513 · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,512.88 |
| Education | $368.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,020.33 | 2019-2025 | |
| Janssen Biotech, INC. | $1,686.19 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $1,502.56 | 2019-2025 | Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $1,407.28 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $1,316.01 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Astrazeneca Pharmaceuticals LP | $1,240.54 | 2019-2025 | Lynparza, Calquence, Tagrisso |
| Genentech USA, INC. | $1,209.72 | 2019-2025 | Polivy, Lunsumio, Tecentriq |
| Pfizer INC. | $978.31 | 2019-2025 | |
| Genzyme Corporation | $783.74 | 2019-2025 | |
| Incyte Corporation | $566.19 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Astellas Pharma US INC | $562.88 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Celgene Corporation | $555.26 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $549.11 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $484.94 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $442.77 | 2019-2025 | Venclexta |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.